Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 334 for prevention of PACAP-38-induced migraine-like attacks
NL-OMON45872Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in migraine comparing AMG 334 with Placebo (2 arms). Primary endpoint: Occurrence of a migraine-like attack within 24 hours of challenge-agent infusion. Started Mar 2017; status: active, not recruiting.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NL-OMON45872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45872.